Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

Cancer Treatment Reviews - Tập 70 - Trang 209-222 - 2018
Jorge Barriuso1, Ana Custodio2, Ruth Afonso3, Vicente Alonso4, Aurora Astudillo5, Jaume Capdevila6, Rocío García-Carbonero7, Enrique Grande8, Paula Jimenez-Fonseca9, Mónica Marazuela10, Cristina Rodríguez-Antona11,12, Javier Aller13
1Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, The Christie ENETS Centre of Excellence, UK
2Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain
3Medical Oncology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
4Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
5Pathological Anatomy Service, Hospital Universitario Central de Asturias, Oviedo, Spain
6Vall d’Hebron University Hospital, Vall d’Hebron, Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
7Medical Oncology Department, Hospital Universitario 12 de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain
8Medical Oncology Department, MD Anderson Cancer Center Madrid, Spain
9Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
10Department of Endocrinology, Hospital de la Princesa, Universidad autónoma de Madrid, Instituto Princesa, Madrid, Spain
11Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
12ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain
13Department of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain

Tài liệu tham khảo

Dasari, 2017, Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the United States, JAMA Oncol, 3, 1335, 10.1001/jamaoncol.2017.0589

ÓToole, 2000, Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability and tolerance, Cancer, 88, 770, 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0

Ricci, 2000, Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors, Am J Clin Oncol, 23, 412, 10.1097/00000421-200008000-00020

Garland, 2003, Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience, Aliment Pharmacol Ther, 17, 437, 10.1046/j.1365-2036.2003.01420.x

Toumpanakis, 2009, Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR, Aliment Pharmacol Ther, 30, 733, 10.1111/j.1365-2036.2009.04083.x

Khan, 2011, Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel), Aliment Pharmacol Ther, 34, 235, 10.1111/j.1365-2036.2011.04693.x

Laskaratos, 2016, Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours, Br J Cancer, 115, 1321, 10.1038/bjc.2016.349

Faggiano, 2016, Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life, Oncotarget, 7, 5538, 10.18632/oncotarget.6686

Jann, 2013, Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin, Neuroendocrinology, 98, 137, 10.1159/000353785

Martín-Richard, 2013, Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicenter, open-label, single arm phase II study, BMC Cancer, 13, 427, 10.1186/1471-2407-13-427

Aparicio, 2001, Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours, Eur J Cancer, 37, 1014, 10.1016/S0959-8049(01)00073-9

Ducreux, 2000, The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors, Am J Gastroenterol, 95, 3276, 10.1111/j.1572-0241.2000.03210.x

Bianchi, 2011, The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel, J Endocrinol Invest, 34, 692

Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group, J Clin Oncol, 29, 4656, 10.1200/JCO.2009.22.8510

Rinke, 2017, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival, Neuroendocrinology, 104, 26, 10.1159/000443612

Caplin, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors, N Engl J Med, 371, 224, 10.1056/NEJMoa1316158

Caplin, 2016, Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study, Endocr Relat Cancer, 23, 191, 10.1530/ERC-15-0490

Kvols, 2012, Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study, Endocr Relat Cancer, 19, 657, 10.1530/ERC-11-0367

Wolin, 2013, A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs, J Clin Oncol, 31

Cives, 2015, Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors, Endocr Relat Cancer, 22, 1, 10.1530/ERC-14-0360

Ferolla, 2017, Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial, Lancet Oncol, 18, 1652, 10.1016/S1470-2045(17)30681-2

Ruszniewski, 2017, A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial, Ann Oncol, 28, 1309, 10.1093/annonc/mdx078

Kwekkeboom, 2008, Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival, J Clin Oncol, 26, 2124, 10.1200/JCO.2007.15.2553

Imhof, 2011, Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers, J Clin Oncol, 29, 2416, 10.1200/JCO.2010.33.7873

Hörsch, 2016, Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multiinstitutional registry study with prospective follow-up, Eur J Cancer, 58, 41, 10.1016/j.ejca.2016.01.009

Strosberg, 2017, Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors, N Engl J Med, 376, 125, 10.1056/NEJMoa1607427

Strosberg, 2018, First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors, J Clin Oncol, 36

Kulke, 2014, Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide, Endocr Relat Cancer, 21, 705, 10.1530/ERC-14-0173

Pavel, 2015, Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial, J Clin Endocrinol Metab, 100, 1511, 10.1210/jc.2014-2247

Kulke, 2017, Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome, J Cin Oncol, 35, 14, 10.1200/JCO.2016.69.2780

Pavel, 2018, Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phae 3 trial, End Relat Cancer, 25, 309, 10.1530/ERC-17-0455

Ezziddin, 2014, Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate, J Nucl Med, 55, 183, 10.2967/jnumed.113.125336

Arnold, 1996, Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours, Gut, 38, 430, 10.1136/gut.38.3.430

Aalbersger E, Huizing D, Kulkarni H, Walraven I, De Wit-van Der Veen L, Singh A et al. Parameters to predict overall survival after PRRT – a multivariate analysis in 783 patients. In: 15th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2018. Abstr K02.

Butturini, 2006, Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma, Endocr Relat Cancer, 13, 1213, 10.1677/erc.1.01200

Panzuto, 2006, Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well differentiated entero-pancreatic endocrine carcinoma, Ann Oncol, 17, 461, 10.1093/annonc/mdj113

Marconcini, 2015, Evaluation of predictive factors of efficacy of Somatostatin Analogs (SSA) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): a single centre experience, Eur J Cancer, 51

Baum, 2018, Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms, Oncotarget, 9, 16932, 10.18632/oncotarget.24524

Palazzo, 2013, Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors, Eur J Gastroenterol Hepatol, 25, 232, 10.1097/MEG.0b013e328359d1a6

Shojamanesh, 2002, Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma, Cancer, 94, 331, 10.1002/cncr.10195

Laskaratos F, Megapanou M, Papantoniou D, Hayes A, Von Stempel C, Phillips E et al. Predictors of antiproliferative effect of lanreotide autogel (LA) as first- line therapy for advance neuroendocrine tumors (NETs). In: 15th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2018. Abstr H18.

Mandair, 2017, Predictors of outcome in patients treated with peptide radio-labelled receptor target therapy (PRRT), J Clin Oncol, 35

Wolin, 2015, Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs), J Clin Oncol, 33

Khan, 2013, Circulating tumor cells as prognostic markers in neuroendocrine tumors, J Clin Oncol, 31, 365, 10.1200/JCO.2012.44.2905

Bodei, 2015, Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy, J Clin Endocrinol Metab, 100, E1437, 10.1210/jc.2015-2792

Fernandes, 2012, Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs, Onco Targets Ther, 5, 409, 10.2147/OTT.S36330

Wang, 2017, Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors, Oncol Lett, 13, 1165, 10.3892/ol.2017.5591

Bodei, 2015, Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status, Eur J Nucl Med Mol Imaging, 42, 1341, 10.1007/s00259-015-3075-9

Bodei LA, Kidd MB, Singh AC, Severi SD, Drozdov IE, Nicolini SD, et al. Circulating neuroendocrine transcripts and gene cluster analysis predict the efficacy of PRRT. In: 14th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2017. Abstr N2.

Taboada, 2007, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, Eur J Endocrinol, 156, 65, 10.1530/eje.1.02313

Gatto, 2013, Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly, J Clin Endocrinol Metab, 98, E66, 10.1210/jc.2012-2609

Wildemberg, 2013, Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs, J Endocrinol Invest, 36, 38

Brzana, 2013, Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience, Pituitary, 16, 490, 10.1007/s11102-012-0445-1

Iacovazzo, 2016, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study, Eur J Endocrinol, 174, 241, 10.1530/EJE-15-0832

van Adrichem, 2016, Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response?, Neuroendocrinology, 103, 560, 10.1159/000441604

Diakatou, 2011, Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study, Endocr Pathol, 22, 24, 10.1007/s12022-011-9149-8

Sclafani, 2011, Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors, Tumori, 97, 620, 10.1177/030089161109700514

Sampedro-Núñez, 2016, Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors, Oncotarget, 7, 6593, 10.18632/oncotarget.6565

Mehta, 2015, Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors, Medicine (Baltimore), 94, e1281, 10.1097/MD.0000000000001281

Okuwaki, 2013, Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes, Cancer, 119, 4094, 10.1002/cncr.28341

Corleto, 2009, Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas, Neuroendocrinology, 89, 223, 10.1159/000167796

Kim, 2011, Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors, Cancer Res Treat, 43, 181, 10.4143/crt.2011.43.3.181

Pinato, 2014, An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes, Br J Cancer, 110, 115, 10.1038/bjc.2013.682

Yuhong W, Wei W, Kaizhou J, Cheng F, Zhiwei Z, Chenghao S, et al. Expression of somatostatin receptors in gastroenteropancreatic neuroendocrine neoplasm and multicenter retrospective clinical study of octreotide LAR in the treatment of advanced GEP-NET. In: 13th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2016. Abstr H29.

Kaemmerer, 2015, Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers, J Clin Endocrinol Metab, 100, 831, 10.1210/jc.2014-2699

Gahete, 2016, The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients, Oncotarget, 7, 60110, 10.18632/oncotarget.11076

Durán-Prado, 2012, The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells, Oncogene, 31, 2049, 10.1038/onc.2011.389

Puig-Domingo, 2014, The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer, PLoS One, 9, e85527, 10.1371/journal.pone.0085527

Molè, 2015, The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells, Endocrine, 50, 442, 10.1007/s12020-015-0594-x

Durán-Prado, 2010, A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs, J Clin Endocrinol Metab, 95, 2497, 10.1210/jc.2009-2247

Luque, 2015, Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas, Cancer Lett, 359, 299, 10.1016/j.canlet.2015.01.037

Fougner, 2008, Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlated with poor response to octreotide treatment, J Clin Endocrinol Metab, 93, 1211, 10.1210/jc.2007-2272

Barlier, 1999, Impact of gsp oncogene on the expression of genes coding for G(s)alpha, Pit-1, G(i)2 alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity, J Clin Endocrinol Metab, 84, 2759

Gatto, 2016, Low beta-arrestin expression correlates with the responsiveness to long-term somatostatinanalog treatment in acromegaly, Eur J Endocrinol, 174, 651, 10.1530/EJE-15-0391

Theodoropoulou, 2006, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression, Cancer Res, 66, 1576, 10.1158/0008-5472.CAN-05-1189

Theodoropoulou, 2009, Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly, Int J Cancer, 125, 2122, 10.1002/ijc.24602

Heliovaara, 2009, The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas, Am J Pathol, 175, 2501, 10.2353/ajpath.2009.081131

Daly, 2010, Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study, J Clin Endocrinol Metab, 95, E373, 10.1210/jc.2009-2556

Chahal, 2012, Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway, J Clin Endocrinol Metab, 97, E1411, 10.1210/jc.2012-1111

Kluge A, Baum R, Kulkarni H, Niepsch K, Bitterlich N, Sayeg M et al. Predictive value of baseline hematology parameters on outcome of 177Lu-DOTATOC PRRT. In: 14th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2016. Abstr N10.

Grenader, 2015, Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel, Eur J Cancer, 51

Hayes AR, Hosking E, Thomas D, Sjoquist K, Chan DLH, Roach PJ. Peripheral blood biomarkers of systemic inflammation may be prognostic in metastatic gastroenteropancreatic neuroendocrine tumour (GEPNET) patients following 177Lu-DOTATATE (LuTate). In: 14th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2017. Abstr H5.

Gut, 2016, Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls, Arch Med Sci, 12, 1, 10.5114/aoms.2016.57577

Khan, 2016, Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms, Clin Cancer Res, 22, 79, 10.1158/1078-0432.CCR-15-1008

Sabet, 2015, Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine, Eur J Nucl Med Mol Imaging, 42, 1238, 10.1007/s00259-015-3041-6

Sabet, 2017, Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis, Am J Nucl Med Mol Imaging, 7, 74

Caplin M, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlácková E et al. Chromogranin A and PFS outcomes in lanreotide Autogel in patients with metastatic enteropancreatic NETs: Data from the CLARINET study. In: 12th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2012. Abstr 1194.

Massironi, 2010, Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors, Am J Gastroenterol, 105, 2072, 10.1038/ajg.2010.154

Buil-Bruna, 2016, Establishing the quantitative relationship between lanreotide Autogel®, Chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors, AAPS J, 18, 703, 10.1208/s12248-016-9884-3

Bodei, 2016, Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, Eur J Nucl Med Mol Imaging, 43, 839, 10.1007/s00259-015-3250-z

Ballarè, 2005, Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly, J Clin Endocrinol Metab, 90, 4824, 10.1210/jc.2005-0132

Zhou, 2011, The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function, World J Surg, 35, 1715, 10.1007/s00268-010-0939-9

Lania, 2008, Genetic abnormalities of somatostatin receptors in pituitary tumors, Mol Cell Endocrinol, 286, 180, 10.1016/j.mce.2007.08.013

Zatelli, 2017, Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms, Endocr Relat Cancer, 24, R223, 10.1530/ERC-17-0091

Khan, 2011, Circulating tumor cells and EpCAM expression in neuroendocrine tumors, Clin Cancer Res, 17, 337, 10.1158/1078-0432.CCR-10-1776

Meyer T, Higgs K, Hickling M, Houchard A. CALM-NET, a multicentre, exploratory study to assess the clinical value of circulating tumour cells (CTCs) enumeration in patients (Pts) with functioning midgut NETs receiving lanreotide autogel (LAN). In: 14th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2016. Abstr C5.

Roldo, 2006, MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior, J Clin Oncol, 24, 1273, 10.1200/JCO.2005.05.5194

Ruebel, 2010, MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression, Mod Pathol, 23, 246, 10.1038/modpathol.2009.161

Miller, 2016, MicroRNAs associated with small bowel neuroendocrine tumours and their metastases, Endocr Relat Cancer, 23, 835, 10.1530/ERC-16-0044

Lee, 2015, High expression of microRNA-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor, Medicine, 94, e2224, 10.1097/MD.0000000000002224

Li, 2013, MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls, Clin Cancer Res, 19, 3600, 10.1158/1078-0432.CCR-12-3092

Li, 2013, Global microRNA profiling of well differentiated small intestinal neuroendocrine tumors, Mod Pathol, 26, 685, 10.1038/modpathol.2012.216

Li, 2015, Somatostatin analogs treated small intestinal neuroendocrine tumor patients circulating MicroRNAs, PLoS One, 10, e0125553, 10.1371/journal.pone.0125553

Kang, 2014, MicroRNA-27b as a prognostic marker in pancreatic neuroendocrine tumor, J Clin Oncol, 32

Lee, 2012, Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors, Pathol Int, 62, 583, 10.1111/j.1440-1827.2012.02845.x

Modlin, 2013, The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood, PLoS One, 8, e63364, 10.1371/journal.pone.0063364

Modlin, 2014, Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility, Clin Chem, 52, 419

Kidd, 2015, Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status, Endocr Relat Cancer, 22, 561, 10.1530/ERC-15-0092

Modlin, 2014, A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection, Endocr Relat Cancer, 21, 615, 10.1530/ERC-14-0190

Modlin, 2015, The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract, Am J Gastroenterol, 110, 1223, 10.1038/ajg.2015.160

Pavel, 2017, NET blood transcript analysis defines the crossing of the clinical Rubicon: when stable disease becomes progressive, Neuroendocrinology, 104, 170, 10.1159/000446025

Modlin, 2016, Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies, Surgery, 159, 336, 10.1016/j.surg.2015.06.056

Bodei L, Kidd M, Van der Zwan W, Singh A, Severi S, Drozdov I et al. Predicting response to PRRT: development and validation of a blood-based predictive biomarker. In: 15th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2018. Abstr K03.

Fotouhi, 2016, Preoteomics suggests a role for APC-survivin in response to somatostatin analog treatment of neuroendocrine tumors, J Clin Endocrinol Metab, 101, 3616, 10.1210/jc.2016-2028

Kjellman M, Knigge U, Welin S, Grønbæk H, Thiis-Evensen EE, Sørbye H et al. Plasma protein kallikrein-14 strongly predicts pronounced chromogranin A (CgA) response in small Intestinal neuroendocrine tumor (NET) patients after somatostatin analog (SSA) treatment: The Nordic EXPLAIN Biomarker Study. In: 15th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2018. Abstr F08.

Asnacios, 2008, Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors, J Clin Oncol, 26, 963, 10.1200/JCO.2007.12.7431

Pavel, 2016, ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site, Neuroendocrinology, 103, 172, 10.1159/000443167

Sevilla, 2016, Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program, BMC Cancer, 16, 858, 10.1186/s12885-016-2901-1

Murray, 2004, Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis, J Clin Invest, 114, 349, 10.1172/JCI19933

Florio, 2003, Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities, Endocrinology, 144, 1574, 10.1210/en.2002-220949

Sadowski, 2016, Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites, J Clin Oncol, 34, 588, 10.1200/JCO.2015.64.0987

Haidar, 2017, The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers, Nuc Med Commun, 38, 170, 10.1097/MNM.0000000000000623

Krausz, 2011, 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (ctreoScan®), Mol Imaging Biol, 13, 583, 10.1007/s11307-010-0374-1

Kratochwil, 2015, SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors, Mol Imaging Biol, 17, 313, 10.1007/s11307-014-0795-3

Öksüz, 2014, Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?, Diagn Interv Imaging, 95, 289, 10.1016/j.diii.2013.07.006

Koch, 2014, Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography, Mol Imaging, 13, 10.2310/7290.2014.00009

Ladwa R, Pattison D, Smith J, Goodman S, Burge M, Rose S et al. Positron emission tomography (PET) predictors of tumor response to peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors (NET). In: 15th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2018. Abstr K11.

Ladwa R, Pattison D, Smith J, Goodman S, Burge M, Rose S et al. Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. In: 15th Annual ENETS Conference for the diagnosis and treatment of neuroendocrine tumours disease; 2018. Abstr K13.

Gabriel, 2009, 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy, J Nucl Med, 50, 1427, 10.2967/jnumed.108.053421

Garske-Román, 2018, Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity, Eur J Nucl Med Mol Imaging, 45, 970, 10.1007/s00259-018-3945-z

Thông tin
Thông tin xuất bản

Cancer Treatment Reviews

Tập 70

209-222

Thông tin tác giả